Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

~ Study met primary endpoint with 47.4% objective response rate ~ Safety and tolerability profile consistent with previously reported data ~ Planned BLA submission on track for later this year ~ Conference call to be held today, Tuesday, January 25, 2022, at 8:30 AM ET

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here